Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial - Summary - MDSpire

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

  • By

  • Chao Wu

  • Xuping Niu

  • Xiaohua Wang

  • Juan Su

  • Hengguang Zhao

  • Mao Lin

  • Chunjun Yang

  • Xiaoming Qin

  • Shuping Guo

  • Cunhuo Jiang

  • Hui Tang

  • Haijing Yang

  • Liming Wu

  • Min Zhu

  • Aihua Wei

  • Xiaohua Tao

  • Yiwen Zhang

  • Chang Shu

  • Jiawei Liu

  • Lu Yang

  • Yuetong Qian

  • Bingjie Zhang

  • Shiyu Zhang

  • Junfang Xu

  • Yang Lu

  • Mingjia Peng

  • Shizheng Luo

  • Weijie Ma

  • Hongzhong Jin

  • May 18, 2026

  • 0 min

Share

Objective:

To assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 1.5% ruxolitinib gel (HDM3010) in adults with prurigo nodularis, highlighting its potential advantages over existing treatments.

Key Findings:
  • 1.5% ruxolitinib gel (HDM3010) shows improved safety profile and pharmacokinetics compared to the cream formulation, with specific metrics indicating reduced systemic exposure.
  • Preliminary efficacy data indicate potential benefits in reducing pruritus and skin lesions, warranting further exploration.
Interpretation:

The study suggests that HDM3010 may offer a promising topical treatment option for prurigo nodularis, with enhanced safety and efficacy, potentially changing the treatment landscape.

Limitations:
  • Small sample size of 48 participants may limit generalizability and introduce biases.
  • Short study duration may not capture long-term effects, necessitating further research.
Conclusion:

HDM3010 demonstrates a favorable safety and pharmacokinetic profile, warranting further investigation in larger trials to confirm its efficacy.

Original Source(s)

Safety, Pharmacokinetics, and Efficacy of 1.5% Ruxolitinib Gel (HDM3010) in Adult Patients with Prurigo Nodularis: A Phase I/II, Randomized, Double-Blind, Vehicle-Controlled Multicenter Clinical Trial

  • by Chao Wu, Xuping Niu, Xiaohua Wang, Juan Su, Hengguang Zhao, Mao Lin, Chunjun Yang, Xiaoming Qin, Shuping Guo, Cunhuo Jiang, Hui Tang, Haijing Yang, Liming Wu, Min Zhu, Aihua Wei, Xiaohua Tao, Yiwen Zhang, Chang Shu, Jiawei Liu, Lu Yang, Yuetong Qian, Bingjie Zhang, Shiyu Zhang, Junfang Xu, Yang Lu, Mingjia Peng, Shizheng Luo, Weijie Ma, Hongzhong Jin

  • May 18, 2026

Related Content

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.

Ivermectin vs Permethrin for Scabies

Investigators evaluate household-level cure rates in dermoscopy-confirmed cases at day 28.

Connecting the Diagnostic Dots in HIES

Clinical case report highlights how classic features of STAT3 hyper-IgE syndrome can be routinely missed in pediatric practice